Introduction
Recent years have seen the production of various forms of slow-release iron preparations. It is claimed that such preparations produce fewer side-effects than the conventional forms of iron treatment, and that absorption is more efficient because the iron is released in the intestine. A clinical trial carried out by Israels and Cook (1965) suggested that the therapeutic response to one tablet of Ferro-Gradumet (105 mg. of iron) daily was about the same as that obtained with one ferrous sulphate tablet (180 mg. of iron) taken three times a day after meals. Iron taken with food is only about half as well absorbed as when taken between meals (Brise and Hallberg, 1962) , and it therefore seemed of interest to compare the response to a single daily dose of Ferro-Gradumet (a slow-release preparation of ferrous sulphate) with that obtained with a similar dose of a conventional iron preparation given once daily before breakfast.
59Fe-labelled therapeutic preparations of iron show great variation in absorption between individuals with comparable degrees of anaemia (Callender and Warner, 1969) ; the present study was therefore designed to compare the effect of the two iron preparations in the same individual.
Materials and Methods
Patients with untreated iron-deficiency anaemia were asked to take part in an investigation of some new forms of iron treatment. They were told that they would be required to attend at fortnightly intervals to have a blood count and to be supplied with tablets. Each subject was allotted three packets, A, B, and C, all containing 14 tablets. A and C were either FerroGradumet or ferrous fumarate with a red film coating, very similar in appearance to that of Ferro-Gradumet. The ferrous fumarate provided 100 mg. of iron per tablet, and the FerroGradumet 105 mg. Packet B contained 14 placebo tablets, identical in appearance with ferrous fumarate. The two periods of iron treatment were therefore separated by two weeks of placebo treatment in every instance.
The majority of subjects were women in whom it was suspected that menorrhagia was causing their anaemia, and in these the trial was so arranged that the menstrual period fell within the placebo fortnight. The two weeks between active treatment allowed the serum iron to return to the initial low value and the blood count to stabilize again.
The patients were instructed to take one tablet first thing each morning before breakfast. The doctor in charge was not aware of the identity of the tablets in packets A or C.
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D Results
The trial began with 30 subjects, but for various reasons full data were obtained in only 19. One woman was admitted to hospital for gynaecological examination during the trial ; two were inadvertently given other iron therapy during the trial; two subjects each lost one packet of tablets; four missed one or other of their appointments; and two discontinued treatment because of intolerance. The last-mentioned two declared that each tablet in turn, including the placebo, made them sick, and though they claimed to have made a real attempt to take the tablets they stopped taking them after one or two days.
Of the 19 who completed the trial the mean increase in haemoglobin during treatment with ferrous fumarate was 1 52 g. in two weeks, and with Ferro-Gradumet 1-35 g. (see Table) . The t test for the paired observations in the individual subjects showed no significant difference in the response to the two preparations (t=0 5324). Apart from the two subjects who discontinued treatment, none reported anything more than minor disturbance of bowel habit, and noted no difference between the treatment regimens. Discussion That only two-thirds of the subjects completed the full trial satisfactorily indicates the difficulty in obtaining properly controlled observations of the response to iron treatment. From the 19 who did complete the test it appears that 100 mg. of iron as a single daily dose of ferrous fumarate is as effective as the slow-release type of iron, Ferro-Gradumet, and in these subjects it did not produce any greater side-effects.
In other studies in which fewer side-effects have been noted with slow-release iron than with conventional iron therapy the comparison has been made with a thrice-daily regimen in different subjects (Ziehm and Likos, 1966; Gomez and Gomez, 1967) . The extremely high instance of over 70% of side-effects from the use of ferrous sulphate reported by Gomez and Gomez is very different from the 20-3n0% found by Hallberg and Solvell (1966) in their careful double-blind trials in a total of 532 29 November 1969
Slow-release Iron-Callender MEBRISHN over 2,000 subjects. Webster (1962) reported more side-effects from ferrous sulphate taken twice a day than from a similar dose of slow-release ferrous sulphate also taken twice a day. Almost half the subjects he was studying, however, suffered from gastrointestinal irritation or ulcerative colitis, and it is difficult to judge how many of the symptoms were due to underlying disease rather than the iron therapy. In studies in which radioactive iron has been used to investigate the absorption from slow-release preparations (Bothwell, Pirzio-Biroli, and Finch, 1958 ;  Crossland-Taylor, Keeling, and Cromie, 1965) the latter have been shown to be less well absorbed than similar doses of ordinary ferrous sulphate. There is little justification, therefore, for expecting slow-release iron to be more effective in therapy.
The idea of being able to treat patients with a single daily dose is attractive, but it would appear from the present data that no specific benefit is to be derived by using a slow-release preparation.
Ferrous fumarate is less soluble than ferrous sulphate, and in a recent study with 59Fe-labelled pills (Callender and Warner, 1969) it was less well absorbed. This would account for the fact that the therapeutic response of the fumarate is similar to that of slow-release ferrous sulphate. A similar daily dose of quickly released ferrous sulphate would be expected to give a better response.
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